Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | CTSG | P08311 | 2/20 | 0.50 |
| ▸ | CMA1 | P23946 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11355997 | 0.94 | RAB9A (0.66) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL27709158 | 0.85 | ALDH1A1 (0.47) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL10718771 | 0.79 | RAB9A (0.53) | ALDH1A1RAB9AKDM4EATMLMNA | |
| SCHEMBL15146792 | 0.78 | HTT (0.68) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL628141 | 0.77 | KDM4E (0.53) | ALDH1A1KDM4EHPGDTDP1LMNA | |
| SCHEMBL799431 | 0.77 | RAB9A (0.87) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL2443715 | 0.77 | ALDH1A1 (0.60) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL8507346 | 0.77 | RAB9A (0.87) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL8526512 | 0.77 | RAB9A (0.87) | ALDH1A1RAB9ACTRB1PRSS1CTSG | |
| SCHEMBL10478078 | 0.77 | RAB9A (0.60) | ALDH1A1RAB9ACTRB1PRSS1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114870-B2 | Method of treating disease states using substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110318393-A1 | Substituted Pyrazole Compounds | MIIKANA THERAPEUTICS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318393-A1 | Substituted Pyrazole Compounds | AURKA, AURKC, AURKB | ALDH1A1 3976/4885RAB9A 2298/4885CTRB1 3939/4885 |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | ALDH1A1 2876/4885RAB9A 2328/4885CTRB1 2670/4885 |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | ALDH1A1 3400/4885RAB9A 2145/4885CTRB1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.